REG - AOTI, Inc. - Grant of awards under Long Term Incentive Plan

AotiAnnouncement

23/04/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260423:nRSW5537Ba&default-theme=true

RNS Number : 5537B  AOTI, Inc.  23 April 2026

23 April 2026

 

AOTI, INC. (the "Company" or "Group" or "AOTI")

 

Grant of performance share awards to CEO, CFO and COO under Long Term
Incentive Plan

 

 

AOTI, INC. (AIM: AOTI), a medical technology group focused on delivering
outcomes-based care at home, by more durable healing of wounds and the
prevention of amputations, announces that on 22 April 2026, the Company
granted awards over ordinary shares in the form of options (Performance
Awards) under the AOTI Long Term Incentive Plan (LTIP) to Mike Griffiths, CEO,
Jayesh Pankhania, CFO, and Anthony Moffatt, COO, who are Persons Discharging
Managerial Responsibilities (PDMR), as detailed below:

 

 PDMR              Role  Number of Performance Awards  Exercise Price (GBP)
 Mike Griffiths    CEO   678,471                       0.37
 Jayesh Pankhania  CFO   377,099                       0.37
 Anthony Moffatt   COO   270,672                       0.37

 

The Performance Awards will vest three years from the grant date conditional
on meeting three-year performance conditions as described below.

 

50% of an award is subject to an Adjusted EBITDA(1) performance condition
measured over a three-year period ending 31 December 2028.

 

50% of an award is subject to an Adjusted EBITDA margin(2) performance
condition measured over a three-year period ending 31 December 2028.

 

(1) Adjusted EBITDA is an unaudited non-GAAP measure: Earnings before
interest, taxation, depreciation, amortisation and non-underlying items.

(2) Adjusted EBITDA margin is Adjusted EBITDA divided by Revenue

( )

END

 

 AOTI, INC.

 Dr. Mike Griffiths, Chief Executive Officer         +44 (0)20 3727 1000

 Jayesh Pankhania, Chief Financial Officer           ir@aotinc.net (mailto:ir@aotinc.net)

 Peel Hunt LLP (Nominated Adviser and Joint Broker)

 Dr. Christopher Golden, James Steel                 +44 (0)20 7418 8900

 Panmure Liberum Limited (Joint Broker)              +44 (0)20 3100 2000

 Emma Earl, Will Goode, Mark Rogers

 Rupert Dearden

 FTI Consulting (Financial PR & IR)                  +44 (0)20 3727 1000

 Ben Atwell, Simon Conway,                           AOTI@fitconsulting.com (mailto:AOTI@fitconsulting.com)

 Natalie Garland-Collins

 

ABOUT AOTI, INC.

 

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and
Galway, Ireland, providing innovative solutions to resolve severe and chronic
wounds worldwide. Its products reduce healthcare costs and improve the quality
of life for patients with these debilitating conditions. The Company's
patented non-invasive Topical Wound Oxygen (TWO(2)(®)) therapy has
demonstrated in differentiating, robust, double-blinded randomised controlled
trials (RCT) and real-world evidence (RWE) studies to more durably reduce the
recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88
per cent reduction in hospitalisations and 71 per cent reduction in
amputations over 12 months. TWO(2)(®) therapy can be administered by the
patient at home, improving access to care and enhancing treatment compliance.
TWO(2)(®) therapy has received regulatory clearance from the US (FDA), Europe
(CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products
Administration, Australia (TGA) and in Saudi Arabia. TWO(2)(®) therapy has
also recently received positive coverage recommendations from the Federal
Joint Committee (G-BA) in Germany and National Institute for Health and Care
Excellence (NICE) in the United Kingdom. Also see www.aotinc.net
(http://www.aotinc.net)

( )

( )

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                     1.   Mike Griffiths

                                              2.   Jayesh Pankhania

                                              3.   Anthony Moffatt
 2.  Reason for notification
 a)  Position / status                        1.   CEO

                                              2.   CFO

                                              3.   COO
 b)  Initial notification / amendment         Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     AOTI, INC.
 b)  LEI                                      213800ZGCNDSTWIRK687
 4.  Details of the transaction(s): section to be repeated for (i) each type of

     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place

     where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares
 b)  Identification code                      US03690C1027
 c)  Nature of transactions                   Award under the AOTI LTIP
 d)  Price(s) and volume(s)                   Exercise Price:

                                              1.   GBP0.37

                                              2.   GBP0.37

                                              3.   GBP0.37

                                              Volume:

                                              1.   678,471

                                              2.   377,099

                                              3.   270,672
 e)  Aggregated Information

     -     Aggregated volume                  As for d) above

     -     Price
 f)  Date of the transactions                 22 April 2026
 g)  Place of the transactions                Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBLGDSIDDDGLD



            Copyright 2019 Regulatory News Service, all rights reserved